Under St Gallen treatment was more frequent in patients with pathological stage 0 (RRR = 21.6, 95% CI 7.221–64.5), poorly differentiated cancer (RRR = 1.88, 95% CI 1.21–2.93) or missing grade of differentiation (RRR = 3.72, 95% CI 2.21–6.29), cancers positive to HER2 receptors (RRR = 3.44, 95% CI 2.40–4.93) and luminal B and HER2 intrinsic subtypes (RRR = 3.63, 95% CI 2.59–5.09 and RRR = 4.38, 95% CI 2.23–8.60, respectively) (Table 4). The gene discussed is ERBB2; the disease is cancer.